Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
No one on the platform currently holds AXNX.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-09-30 | 53,800 | $3.7M |
No one on the platform has traded AXNX yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $640M | +19.5% | $1.20 | $0.78–$1.97 | 59.2× | 6 |
| 2027 | $768M | +19.9% | $2.04 | $2.04–$2.04 | 34.9× | 2 |
| 2028 | $905M | +17.9% | $2.83 | $2.83–$2.83 | 25.1× | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2024-11-07 | $0.13 | $0.16 | +23.1% |
| 2024-08-01 | $0.13 | $0.13 | +0.0% |
| 2024-04-30 | $-0.05 | $-0.38 | -660.0% |
| 2024-02-28 | $0.06 | $0.13 | +116.7% |
| 2023-10-30 | $-0.05 | $0.08 | +260.0% |
| 2023-07-27 | $-0.12 | $-0.15 | -25.0% |
| 2023-05-01 | $-0.34 | $-0.19 | +44.1% |
| 2023-03-01 | $-0.24 | $0.01 | +104.2% |
| $4.7B |
| — |
| NUVANuVasive, Inc. | $39.75 | -2.24% | $2.1B | — |
| OLKOlink Holding AB (publ) | $26.08 | +0.31% | $3.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
$NARI After $AXNX , this was on radar. Looking at current GLP-1 demand , $VKTX $ALT
View on StockTwits ↗
$AXNX Axonics, Inc. (NASDAQ:AXNX): A Pioneering Force in Bladder and Bowel Dysfunction Management https://beyondspx.com/article/axonics-inc-nasdaq-axnx-a-pioneering-force-in-bladder-and-bowel-dysfunction-management
View on StockTwits ↗
$AXNX At a special meeting held on March 22, 2024 the shareholders of Axonics, Inc. (AXNX) approved a merger with Boston Scientific Corp (BSX) . The merger is tentatively scheduled to close prior to the market open on November 15, 2024. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on November 14, 2024. If the merger closes as anticipated, the stock will remain halted on the day of closing (November 15th) and will be suspended effective November 18, 2024 https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2024-557
View on StockTwits ↗
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Axonics Modulation Technologies Inc. Is that bullish or bearish? $AXNX #RsiOverbought #NASDAQ
View on StockTwits ↗
Climbing higher with $AXNX! RSI: 68.7% 50-day MA: $69.34 200-day MA: $68.19
View on StockTwits ↗Riding the momentum wave! Buy a CALL on $AXNX at strike None! RSI: 69.78% 50-day MA: $69.13 200-day MA: $67.87
View on StockTwits ↗Who’s looking for the exits with $AXNX? RSI: 72.82% 50-day MA: $69.1 200-day MA: $67.83
View on StockTwits ↗Who's planning to sell $AXNX? RSI: 72.82% 50-day MA: $69.1 200-day MA: $67.83
View on StockTwits ↗
$AXNX new insider selling: 2961 shares. http://insiderbuyingselling.com/?t=AXNX
View on StockTwits ↗
$AXNX Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia https://www.stocktitan.net/news/AXNX/axonics-receives-regulatory-approval-for-fourth-generation-3ovsgvazbyi0.html
View on StockTwits ↗
Signal alert: $AXNX - Double Bottom https://stockinvest.us/l/TDYISiSl2O
View on StockTwits ↗
$AXNX $MDT Axonics prevails in patent infringement lawsuit with Medtronic Axonics (AXNX) announced that the jury has returned a unanimous verdict in the patent infringement lawsuit brought by Medtronic (MDT) against Axonics in U.S. District Court for the Central District of California. The jury found that Axonics does not infringe any of the three patents-in-suit. "A jury of our peers recognized that Axonics' proprietary tined lead design and temperature sensor technology is differentiated from our competitor's intellectual property," said Raymond W. Cohen, chief executive officer. "As we have said since this case was first filed in late 2019, our view is that Medtronic's lawsuit was initiated to stifle competition, limit patient and physician choice, and protect the incumbent's monopoly in sacral neuromodulation. We are very pleased with the jury's finding and continue to remain focused on fulfilling our mission of positively impacting the lives of adults with bladder and bowel dysfunction."
View on StockTwits ↗$AXNX Axonics Prevails in Patent Infringement Lawsuit with Medtronic https://www.stocktitan.net/news/AXNX/axonics-prevails-in-patent-infringement-lawsuit-with-8kt1pxdoa3dc.html
View on StockTwits ↗Signal alert: $AXNX - GoldenStar https://stockinvest.us/l/XTK7XfiU7A
View on StockTwits ↗Signal alert: $AXNX - GoldenStar https://stockinvest.us/l/8awVuuaKhq
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.